Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors

Regulatory Toxicology and Pharmacology

Volumn 30, Issue 2 II, 1999, Pages

  Dybing, Erik ^a   Søderlund, Erik J ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

CONFERENCE PAPER; DNA POLYMORPHISM; DRUG INACTIVATION; FETUS; HUMAN; HUMAN TISSUE; LIVER METABOLISM; METABOLIC REGULATION; NEWBORN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICOKINETICS; URINARY EXCRETION;

EID: 0032721915     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1999.1322     Document Type: Conference Paper

References (16)

1. Au, W. W., Wilkinson, G. S., Tyring, S. K., Legator, M. S., El Zein, R., Hallberg, L., and Heo, M. Y. (1996). Monitoring populations for DNA repair deficiency and for cancer susceptibility. Environ. Health Perspect. 104(Suppl. 3), 579-584.
2. Barnett, Y. A., and King, C. M. (1995). An investigation of antioxidant status, DNA repair capacity and mutation as a function of age in humans. Mutat. Res. 338, 115-128.
3. Bartsch, H., and Hietanen, E. (1996). The role of individual susceptibility in cancer burden related to environmental exposure. Environ. Health Perspect. 104(Suppl. 3), 569-577.
4. Bennett, W. M. (1997). Overview: Clinical aspects of nephrotoxicity. In Comprehensive Toxicology. Vol. 7, Renal Toxicology (R. S. Goldstein, Vol. Ed.; I. G. Sipes, C. A. McQueen, and A. J. Gandolfi, Eds.-in-Chief), pp. 1-19, Elsevier Science, New York.
5. Bjorneboe, A., and Bjorneboe, G. E. (1993). Antioxidant status and alcohol-related diseases. Alcohol Alcohol. 28, 111-116.
6. Clark, D. O. (1997). Pharmacokinetic and structure-activity considerations. In Comprehensive Toxicology. Vol. 10, Reproductive and Endocrine Toxicology (K. Bokelheide, R. E. Chapin, P. B. Hoyer, and C. Haris, Vol. Eds.; I. G. Sipes, C. A. McQueen, and A. J. Gandolfi, Eds.-in-Chief), pp. 499-527, Elsevier Science, New York.
7. Craft, A. W., Brocklebank, J. T., Hey, E. N., and Jackson, R. H. (1974). The »grey toddler«: Chloramphenicol toxicity. Arch. Dis. Child. 49, 235-327.
8. 4 hepatotoxicity. Toxicology 111, 29-42.
9. Gilman, J. T., and Gal, P. (1992). Pharmacokinetic and pharmacodynamic data collection in children. A quiet frontier. Clin. Pharmacokinet. 23, 1-9.
10. Godin, D. V., and Wohaieb, S. A. (1988). Nutritional deficiency, starvation, and tissue antioxidant status. Free Radical Biol. Med. 5, 165-176.
11. Harris, C. (1997). Introduction to developmental toxicology. In Comprehensive Toxicology. Vol. 10, Reproductive and Endocrine Toxicology (K. Boekelheide, R. E. Chapin, P. B. Hoyer, and C. Harris, Vol. Eds.; I. G. Sipes, C. A. McQueen, and A. J. Gandolfi, Eds.-in-Chief), pp. 479-497, Elsevier Science, New York.
12. Hattis, D., Erdreich, L., and Ballew, M. (1987). Human variability in susceptibility to toxic chemicals - A preliminary analysis of pharmacokinetic data from normal volunteers. Risk Anal. 7, 415-426.
13. Hattis, D., and Silver, K. (1994). Human interindividual variability - A major source of uncertainly in assessing risks for noncancer health effects. Risk Anal. 14, 421-431.
14. Hattis, D. (1996). Human interindividual variability in susceptibility lo toxic effects: From annoying detail to a central determinant of risk. Toxicology 111, 5-14.
15. Hawkins, R. A. (1986). Transport of essential nutrients across the blood-brain barrier of individual structures. Fed. Proc. 45, 2005-2059.
16. Hunt, C. M., Westerkam, W. R., and Stave, G. M. (1992). Effect of age and gender on the activity of CYP3A. Biochem. Pharmacol. 44, 275-283.